Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

Fig. 4

Inhibition of p53 is critical for Annexin A2-mediated cisplatin resistance. a-b A549/DDP cells were transfected with Annexin A2 siRNA, a p53 protein expression was analyzed by Western blot; b the expression of p53 and p53-regulated apoptotic genes p21, GADD45, Bcl2, BAX, Puma, and MDM2 were measured by Real time RT-PCR. c-d A549 cells were transfected with pCMV6-Annexin A2, c p53 protein expression was analyzed by Western blot; d p53 and p53-regulated apoptotic genes p21, GADD45, Bcl2, BAX, Puma, and MDM2 were measured by Real time RT-PCR. e A549/DDP cells were co-transfected with Annexin A2 siRNA and p53 siRNA, p53 protein expression was analyzed by Western blot. f A549/DDP cells were co-transfected with Annexin A2 siRNA and p53 siRNA, and then treated with cisplatin at the indicated concentration for 48 h, cell viability was measured by MTT assay. g A549/DDP cells were co-transfected with Annexin A2 siRNA and p53 siRNA, and then treated with 5 μM cisplatin for 48 h, cells were stained with Annexin V-FITC and propidium iodide, and the cell apoptosis were analyzed by flow cytometry. h A549/DDP cells were co-transfected with Annexin A2 siRNA and p53 siRNA, and then treated with 5 μM cisplatin for 24 h, Caspase 3/7 activity were measured. *P < 0.05

Back to article page